← FDA DRUG APPROVALS

FDA ANDA · ANDA205180

NITROFURANTOIN

Sponsor: ACTAVIS MID ATLANTIC

APPLICATION
ANDA205180
TYPE
ANDA
ORIGINAL APPROVAL
2016-05-03
LATEST ACTION
2024-11-12
ROUTE
ORAL
DOSAGE FORM
SUSPENSION
MARKETING STATUS
Prescription

Products

NITROFURANTOINPrescription
NITROFURANTOIN 25MG/5ML · SUSPENSION · ORAL

Approval history

2024-11-12Labeling · Supplement 5 · standardAP
2024-11-12Labeling · Supplement 4 · standardAP
2016-05-03UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →